Physician profile
Gloria Jackson
NPI 1235123423
$4,113.09
in general payments reported to CMS, 2019-2025
33 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $579 · 2021: $796 · 2022: $638 · 2023: $325 · 2024: $574 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $629.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $605.73 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $430.45 | 2019-2025 | |
| Pfizer INC. | $369.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.70 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $297.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $246.17 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $179.73 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $153.20 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.82 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $105.39 | 2022 | |
| Merck Sharp & Dohme LLC | $85.29 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $51.20 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $47.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.56 | 2019-2023 | Camzyos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $44.83 | 2019 | |
| Jazz Pharmaceuticals INC. | $37.86 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $30.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $28.10 | 2024 | |
| Ibsa Pharma INC. | $24.22 | 2019 | |
| Corium, LLC | $22.46 | 2023 | Azstarys |
| Esperion Therapeutics, INC. | $19.94 | 2021 | |
| Bausch Health US, LLC | $18.51 | 2022 | |
| Astellas Pharma US INC | $18.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.84 | 2019 | |
| Insulet Corporation | $16.75 | 2023 | Omnipod |
| Abbott Laboratories | $16.72 | 2024 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $16.15 | 2025 | Azmiro |
| Clarus Therapeutics INC. | $15.66 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.68 | 2020 | |
| Currax Pharmaceuticals LLC | $13.01 | 2020 | |
| Allergan, INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.